Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Amphiregulin, ST2,and REG3α Biomarker Risk Algorithms as Predictors of Non-Relapse Mortality in Patients with Acute GVHD.
Etra AM, El Jurdi N, Katsivelos N, Kwon D, Gergoudis SC, Morales G, Spyrou N, Kowalyk S, Aguayo-Hiraldo P, Akahoshi Y, Ayuk FA, Baez J, Betts BC, Chanswangphuwana C, Chen YB, Choe HK, DeFilipp Z, Gleich S, Hexner EO, Hogan WJ, Holler E Prof Dr med, Kitko CL, Kraus S, Al Malki MM, MacMillan ML, Pawarode A, Quagliarella F, Qayed M, Reshef R, Schechter-Finkelstein T, Vasova I, Weisdorf DJ, Wölfl M, Young R, Nakamura R, Ferrara JLM, Levine JE, Holtan SG. Etra AM, et al. Among authors: vasova i. Blood Adv. 2024 Apr 19:bloodadvances.2023011049. doi: 10.1182/bloodadvances.2023011049. Online ahead of print. Blood Adv. 2024. PMID: 38640195
A Day 14 Endpoint for Acute GVHD Clinical Trials.
Spyrou N, Akahoshi Y, Kowalyk S, Morales G, Beheshti R, Aguayo-Hiraldo P, Al Malki MM, Ayuk F, Bader P, Baez J, Capellini A, Choe H, DeFilipp Z, Eder M, Eng G, Etra A, Gleich S, Grupp SA, Hexner E, Hoepting M, Hogan WJ, Kasikis S, Katsivelos N, Khan A, Kitko CL, Kraus S, Kwon D, Merli P, Portelli J, Qayed M, Reshef R, Schechter T, Vasova I, Wölfl M, Wudhikarn K, Young R, Holler E, Chen YB, Nakamura R, Levine JE, Ferrara JLM. Spyrou N, et al. Among authors: vasova i. Transplant Cell Ther. 2024 Apr;30(4):421-432. doi: 10.1016/j.jtct.2024.01.079. Epub 2024 Feb 4. Transplant Cell Ther. 2024. PMID: 38320730 Free article.
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD.
DeFilipp Z, Kim HT, Spyrou N, Katsivelos N, Kowalyk S, Eng GW, Kasikis S, Beheshti R, Baez J, Akahoshi Y, Ayuk FA, Choe HK, Etra AM, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Qayed M, Reshef R, Vasova I, Zeiser R, Young R, Holler E Prof Dr med, Ferrara JLM, Nakamura R, Levine JE, Chen YB. DeFilipp Z, et al. Among authors: vasova i. Blood Adv. 2024 Apr 19:bloodadvances.2024012561. doi: 10.1182/bloodadvances.2024012561. Online ahead of print. Blood Adv. 2024. PMID: 38640197
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, Aigner M, Rothe T, Minopoulou I, Tur C, Knitza J, Kharboutli S, Kretschmann S, Vasova I, Spoerl S, Reimann H, Munoz L, Gerlach RG, Schäfer S, Grieshaber-Bouyer R, Korganow AS, Farge-Bancel D, Mougiakakos D, Bozec A, Winkler T, Krönke G, Mackensen A, Schett G. Müller F, et al. Among authors: vasova i. N Engl J Med. 2024 Feb 22;390(8):687-700. doi: 10.1056/NEJMoa2308917. N Engl J Med. 2024. PMID: 38381673
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis.
Akahoshi Y, Spyrou N, Hoepting M, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe HK, Eder M, Etra AM, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Kraus S, Al Malki MM, Merli P, Qayed M, Reshef R, Schechter T, Ullrich E, Vasova I, Wölfl M, Zeiser R, Baez J, Beheshti R, Eng G, Gleich S, Kasikis S, Katsivelos N, Kowalyk S, Morales G, Young R, DeFilipp Z, Ferrara JLM, Levine JE, Nakamura R. Akahoshi Y, et al. Among authors: vasova i. Blood Adv. 2024 Apr 23;8(8):2047-2057. doi: 10.1182/bloodadvances.2023012091. Blood Adv. 2024. PMID: 38324721 Free PMC article.
Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
Pytlík R, Belada D, Kubáčková K, Vášová I, Kozák T, Pirnos J, Bolomská I, Matuška M, Přibylová J, Campr V, Burešová L, Sýkorová A, Berková A, Klener P, Trněný M; Czech Lymphoma Study Group. Pytlík R, et al. Among authors: vasova i. Leuk Lymphoma. 2015 Jan;56(1):57-64. doi: 10.3109/10428194.2014.904509. Epub 2014 Apr 29. Leuk Lymphoma. 2015. PMID: 24628294
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial (MInT) Group. Pfreundschuh M, et al. Lancet Oncol. 2011 Oct;12(11):1013-22. doi: 10.1016/S1470-2045(11)70235-2. Epub 2011 Sep 21. Lancet Oncol. 2011. PMID: 21940214 Clinical Trial.
52 results